-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, 2:30-3:30 p.m. ET.
-
Warren and colleagues performed a nonrandomized pre- and postobservational trial of an educational intervention to prevent catheter-associated bloodstream infections (CABSIs) in a 500-bed private community hospital in Missouri.
-
To determine practices regarding use of closed-system suctioning (CSS) and airway management of intubated patients, Sole and colleagues surveyed a national sample of 1665 registered nurses (RNs) and respiratory therapists (RTs) in 27 institutions.
-
A wide variety of therapeutic interventions have failed to produce a significant change in the mortality of critically ill patients. Studies of these interventions include numerous trials of anti-inflammatory agents in sepsis, the trial involving growth hormone in critically ill patients, as well as a host of other investigations.
-
The ARDSNetwork trial that began in 1996 (ARMA trial)1 was designed to test the validity of using lower tidal volumes in mechanical ventilators was halted because critics who were not a part of the ARDSNetwork argued that the control arm chosen was harmful and unethical.
-
Specialty beds marketed for ICU patients range from simple air-filled mattresses designed for use on ordinary hospital beds to high-tech, electronically controlled rotating or vibrating devices.
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.
-
-
Of 26 mechanically ventilated patients, 22 developed bacterial lower respiratory tract colonization, and in 15 patients anaerobes were recovered; 2 of 5 patients diagnosed with ventilator-associated pneumonia had anaerobes present in sufficient quantity to suggest that they were considered pathogenic.
-
The appearance of epileptic activity and etiologies of seizures vary with age. Anticonvulsant drug therapy optimally should stop seizure activity and prevent further brain injury that may later manifest as repeat spontaneous seizures or other neurodevelopmental injury. Since not all types of recurrent or persistent seizure activity are known to cause brain injury, the decision to treat must be individualized. Knowledgeable parents of children with known underlying disease and their pediatric neurologists can provide valuable information that can be integral in management decisions.
